Oyster Point Pharma, Inc. plans to target a broad population with its newly approved nasal spray for signs and symptoms of dry eye disease, Tyrvaya (varenicline solution), including patients currently on other prescription drugs, those who have given up on those therapies and treatment-naïve patients. But commercial success will mean securing formulary placement on a level comparable to existing prescription drugs, particularly AbbVie Inc.’s Restasis (cyclosporine) and Novartis AG’s Xiidra (lifitegrast).
The first nasal spray for dry eye disease, Tyrvaya received US Food and Drug Administration on 18 October and is...
